Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials*

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Review the latest AD management data with Capsule Summaries and gain expert insights from brief commentaries and an on-demand Webcast covering key studies from the 2020 AAAAI, AAD, and RAD conferences.
Andrew F. Alexis, MD, MPH
Jonathan Silverberg, MD

Highlights on Atopic Dermatitis

Review the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.

Andrew F. Alexis, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 10, 2020 Expired: August 9, 2021

With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Gain expert perspectives on the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: November 5, 2020 Expired: November 4, 2021

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue